ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för leniolisib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

15 träffar

Bibliografisk träff 2024-06-01

Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.

Rao VK, Kulm E, Grossman J, Buchbinder D, Chong H, Bradt J, Webster S, Šedivá A, Dalm VA, Uzel G.

Blood Adv · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/bloodadvances.2023011000

Bibliografisk träff 2024-03-08

APDS patients with immune-complex vasculitis and resolution with leniolisib.

Doroudchi MA, Stephens AV, Wang Z, Dhami J, Butte MJ.

Clin Immunol · research-article; journal article · DOI 10.1016/j.clim.2024.110176

Bibliografisk träff 2024-02-12

Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome.

De SK.

Front Pharmacol · data-paper; journal article · DOI 10.3389/fphar.2024.1337436

Bibliografisk träff 2023-12-27

Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.

Berglund LJ.

J Clin Immunol · review-article; review; journal article · DOI 10.1007/s10875-023-01626-0

Bibliografisk träff 2023-10-04

Interim analysis: Open-label extension study of leniolisib for patients with APDS.

Rao VK, Kulm E, Šedivá A, Plebani A, Schuetz C, Shcherbina A, Dalm VA, Trizzino A, Zharankova Y, Webster S, Orpia A, Körholz J, Lougaris V, Rodina Y, Radford K, Bradt J, Relan A, Holland SM, Lenardo MJ, Uzel G.

J Allergy Clin Immunol · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.jaci.2023.09.032

Bibliografisk träff 2023-09-28

PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.

Cant AJ, Chandra A, Munro E, Rao VK, Lucas CL.

J Allergy Clin Immunol Pract · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.jaip.2023.09.016

Bibliografisk träff 2023-07-01

Leniolisib: First Approval.

Duggan S, Al-Salama ZT.

Drugs · review; journal article · DOI 10.1007/s40265-023-01895-4

Bibliografisk träff 2023-05-19

ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome.

Sood AK, Francis O, Schworer SA, Johnson SM, Smith BD, Googe PB, Wu EY.

Front Pediatr · review-article; review; journal article · DOI 10.3389/fped.2023.1179788

Bibliografisk träff 2023-04-15

Leniolisib

Författaruppgift saknas

Tidskrift saknas · review

Bibliografisk träff 2023-03-01

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.

Rao VK, Webster S, Šedivá A, Plebani A, Schuetz C, Schuetz C, Shcherbina A, Conlon N, Coulter T, Dalm VA, Trizzino A, Zharankova Y, Kulm E, Körholz J, Lougaris V, Rodina Y, Radford K, Bradt J, Kucher K, Relan A, Holland SM, Lenardo MJ, Uzel G.

Blood · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1182/blood.2022018546

Bibliografisk träff 2023-01-06

Phosphatidyl Inositol 3-Kinase (PI3K)-Inhibitor CDZ173 protects against LPS-induced osteolysis.

Wu Z, Li X, Chen X, He X, Chen Y, Zhang L, Li Z, Yang M, Yuan G, Shi B, Chen N, Li N, Feng H, Zhou M, Rui G, Xu F, Xu R.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2022.1021714

Bibliografisk träff 2018-11-29

<sup>19</sup>F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers.

Pearson D, Garnier M, Luneau A, James AD, Walles M.

Xenobiotica · randomized controlled trial; journal article · DOI 10.1080/00498254.2018.1523488

Bibliografisk träff 2018-09-01

CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.

De Buck S, Kucher K, Hara H, Gray C, Woessner R.

Biopharm Drug Dispos · clinical trial; journal article · DOI 10.1002/bdd.2157

Bibliografisk träff 2017-09-29

Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.

Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, Rosenzweig SD, Christ AD, Sloth B, Cabanski M, Joshi AD, de Buck S, Doucet J, Guerini D, Kalis C, Pylvaenaeinen I, Soldermann N, Kashyap A, Uzel G, Lenardo MJ, Patel DD, Lucas CL, Burkhart C.

Blood · research-article; journal article · DOI 10.1182/blood-2017-08-801191

Bibliografisk träff 2017-08-25

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Hoegenauer K, Soldermann N, Zécri F, Strang RS, Graveleau N, Wolf RM, Cooke NG, Smith AB, Hollingworth GJ, Blanz J, Gutmann S, Rummel G, Littlewood-Evans A, Burkhart C.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.7b00293